Blood disorders
Aplastic anaemia
再生障碍性贫血
A form of anaemia in which the bone marrow does not make enough blood cells.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 63
- cities
- 31
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 32% of the world's English-language research papers on aplastic anaemia, 2021–2025 (21% in 2016–2020), and 19% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
63 hospitals in 31 cities
Order: papers led on aplastic anaemia, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on aplastic anaemia, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
- 48 papers led
- 29 papers led
- 24 papers led
- 23 papers ledNo open trial led
- 16 papers led
- 13 papers ledNo open trial led
- 11 papers led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 36
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 71 papers led3 hospitals
- 30 papers led2 hospitals
- 23 papers led1 hospital
- 15 papers led6 hospitals
- 15 papers led2 hospitals
- 14 papers led3 hospitals
- 12 papers led3 hospitals
- 11 papers led3 hospitals
- 10 papers led2 hospitals
- 9 papers led2 hospitals
- 8 papers led2 hospitals
- 7 papers led2 hospitals
- 6 papers led3 hospitals
- 6 papers led2 hospitals
- 6 papers led2 hospitals
- 6 papers led5 hospitals
- 4 papers led1 hospital
- 4 papers led1 hospital
- 4 papers led1 hospital
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led3 hospitals
- 3 papers led3 hospitals
- 3 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 0 papers led0 hospitals
open trials on aplastic anaemia in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 22 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingRomiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07400341
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingAdverse Effects of ATG/ALG Therapy in Aplastic Anemia
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07461116
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07586735
Age 40 years to 60 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingPeripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07629947
Age 18 years to 40 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingPhase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07714512
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06802055
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingReproductive and Mental Health of Patients With Aplastic Anemia
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06936930
Age 18 years to 40 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingDose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07010237
Age 65 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Prediction Model in Pregnant Women With Aplastic Anemia
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07101770
Age 20 years to 50 years; women only (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingThe Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07287228
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07499284
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow University; 2 listed hospitals as study sitesHangzhou, Suzhou, Xuzhou
- RecruitingBrain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
- Phase
- Not given
- Started
- 2025-10
- Registry
- NCT07578675
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
- Phase
- Early phase 1
- Started
- 2024-10
- Registry
- NCT06633328
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingUmbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06650553
Age 6 years to 75 years (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingRituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
- Phase
- Phase 2
- Started
- 2023-02
- Registry
- NCT06254560
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingHigh-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT07205523
Age not stated (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingConditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
- Phase
- Phase 2
- Started
- 2027-08
- Registry
- NCT07885982
Age 1 year to 50 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- Not yet recruitingClinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07552506
Age 14 years to 50 years; women only (registered criteria)
Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou
- Not yet recruitingStudy of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Registry
- NCT06791824
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingTreatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT06964971
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhou
- Not yet recruitingEfficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07078721
Age 18 years to 50 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Enrolling by invitationPhase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
- Phase
- Phase 1/Phase 2
- Started
- 2022-08
- Registry
- NCT07299123
Age 6 years to 60 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Standards for 10 childhood blood diseases and cancers (2019 edition)National Health Commission 国卫办医函〔2019〕716号, 2019-09-05; children
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.